Join Richmond Pharmacology next month for the DIA Cardiovascular Safety and State-of-the-art Development Issues meeting taking place 17 to 18 April 2012 in Washington.The meeting will address present issues surrounding Type 2 Diabetes Mellitus Medications, QT, Benefit/Risk Assessment, Arrhythmias, Thrombosis, and Cardiotoxicity during a series of debate-style presentations from international industry, academic, and regulatory speakers.Dr Jorg Taubel's current research is concerned with the cardiovascular effects of meals, insulin and C-peptide in Caucasian and Japanese populations. He will be presenting some of his most recent findings on Day 2 (18 Apr 2012), covering the following topics of discussion:Session 6, CV Safety Track at 10h30:

  • Moxifloxacin effect on the QTc interval in fed and fasted states in Thorough QT studies

Session 4, Diabetes Track at 11h00:

  • Insulin does not prolong the QT interval in thorough QT studies performed in healthy volunteers

For further information on Richmond Pharmacology�s specialist Cardiovascular Safety expertise or to request a copy of our latest TQT publication, contact a member of our Business Development team today. Alternatively we hope to see you in the US next month!

Latest news

Single-dose gene silencing cure for fatal heart disease comes one step closer

March 20, 2024
Richmond is delighted to be part of the first large-scale in-human trial of a genetic cure for ATTR Amyloidosis
Read more

How Does Social Time Contribute to a Positive Workplace Culture?

March 13, 2023
Read the blog by Richmond Pharmacology’s Chair of the Social Committee and Head of Marketing, Elizabeth Romano about how being social improves organisational culture and embeds the core values.
Read more

Events

ISA Symposium 2024

29-30 May 2024 
We will be attending the XIX International Symposium on Amyloidosis, taking place in Rochester, Minesota
View event